|
|
|
Insider
Information: |
Shah Nimish P |
Relationship: |
Director |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
50,221,732 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$422,736,027 |
|
|
Total
Shares |
50,221,732 |
|
|
Total
Value |
$422,736,027 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
66
|
4
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
62
|
4
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
Percentage
Gain/Loss : |
-56.4%
|
-384.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Bellerophon Therapeutics Inc |
BLPH |
10% Owner |
2018-08-14 |
0 |
2018-09-17 |
7,386,163 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
10% Owner |
2019-03-18 |
0 |
2024-02-08 |
4,824,731 |
Premium* |
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
|
0 |
2019-12-13 |
4,016,873 |
Premium* |
|
Altimmune, Inc |
ALT |
10% Owner |
2020-05-26 |
0 |
2021-02-25 |
3,500,000 |
Premium* |
|
Cogent Biosciences, Inc. |
COGT |
10% Owner |
2020-08-14 |
0 |
2020-08-18 |
4,355,273 |
Premium* |
|
Tricida, Inc. |
TCDA |
10% Owner |
2022-06-02 |
0 |
2022-10-26 |
3,751,406 |
Premium* |
|
Vistagen Therapeutics Inc |
VTGN |
10% Owner |
|
0 |
2022-07-12 |
20,637,286 |
Premium* |
|
Apogee Therapeutics, Inc. |
APGE |
Director |
2023-07-13 |
0 |
2023-07-13 |
1,750,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-02-08 |
4 |
B |
$14.70 |
$437,281 |
I/I |
29,747 |
4,824,731 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-02-07 |
4 |
B |
$14.56 |
$754,601 |
I/I |
51,827 |
4,794,984 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-02-06 |
4 |
B |
$14.74 |
$65,947 |
I/I |
4,474 |
4,743,157 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-30 |
4 |
B |
$14.47 |
$1,274,793 |
I/I |
88,099 |
4,738,683 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-29 |
4 |
B |
$14.22 |
$1,146,132 |
I/I |
80,600 |
4,650,584 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-26 |
4 |
B |
$12.98 |
$54,179 |
I/I |
4,174 |
4,569,984 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-25 |
4 |
B |
$12.73 |
$89,492 |
I/I |
7,030 |
4,565,810 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-24 |
4 |
B |
$12.44 |
$257,334 |
I/I |
20,686 |
4,558,780 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-23 |
4 |
B |
$12.54 |
$136,648 |
I/I |
10,897 |
4,538,094 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-22 |
4 |
B |
$12.55 |
$847,702 |
I/I |
67,546 |
4,527,197 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-19 |
4 |
B |
$12.43 |
$310,750 |
I/I |
25,000 |
4,459,651 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-18 |
4 |
B |
$12.51 |
$496,397 |
I/I |
39,680 |
4,434,651 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-17 |
4 |
B |
$12.60 |
$994,455 |
I/I |
78,925 |
4,394,971 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-16 |
4 |
B |
$12.73 |
$249,495 |
I/I |
19,599 |
4,316,046 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-11 |
4 |
B |
$12.68 |
$84,284 |
I/I |
6,647 |
4,296,447 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-10 |
4 |
B |
$12.67 |
$604,359 |
I/I |
47,700 |
4,289,800 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-09 |
4 |
B |
$12.56 |
$261,449 |
I/I |
20,816 |
4,242,100 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-08 |
4 |
B |
$12.44 |
$860,649 |
I/I |
69,184 |
4,221,284 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-04 |
4 |
B |
$12.11 |
$505,762 |
I/I |
41,764 |
4,152,100 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2024-01-03 |
4 |
B |
$12.20 |
$214,781 |
I/I |
17,605 |
4,110,336 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2023-12-29 |
4 |
B |
$12.49 |
$75,102 |
I/I |
6,013 |
4,092,731 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2023-12-28 |
4 |
B |
$12.50 |
$5,893,625 |
I/I |
471,490 |
4,086,718 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2023-12-27 |
4 |
B |
$11.97 |
$496,923 |
I/I |
41,514 |
3,615,228 |
1.5 |
% |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2023-12-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,573,714 |
|
% |
|
APGE |
Apogee Therapeutics, Inc. |
Director |
|
2023-07-13 |
4 |
B |
$17.00 |
$29,750,000 |
I/I |
1,750,000 |
1,750,000 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|